早期关节炎非药物与药物干预:2016年EULAR推荐系统文献综述
该系统文献综述由欧洲抗风湿病联盟(EULAR)专家组为更新2016年早期关节炎管理推荐而开展,检索MEDLINE、EMBASE和Cochrane数据库及2014-2015年ACR/EULAR会议摘要。综述确认运动项目可改善早期关节炎患者疼痛和躯体功能,症状出现3个月内治疗者临床和影像学结局优于3个月后治疗者,糖皮质激素(GC)临床和影像学疗效得到确认但长期使用的心血管安全性令人担忧,甲氨蝶呤和GC可作为一线药物。
要点
- 运动项目可能改善早期关节炎患者疼痛和躯体功能
- 症状出现3个月内治疗者临床和影像学结局优于3个月后治疗
- 甲氨蝶呤和GC可作为一线药物,但GC长期使用需关注心血管安全性
核心结论
- 综述结果确认运动项目的益处以及早期药物治疗和紧密控制的重要性。
- 综述支持甲氨蝶呤和GC作为一线药物使用,但GC长期使用存在安全性顾虑。
研究设计与样本
- EULAR专家委员会定义关于非药物干预、患者信息与教育、NSAID、GC和DMARD使用及疾病监测的研究问题。
主要发现
- 运动项目可能改善早期关节炎患者疼痛和躯体功能。
- 症状出现3个月内治疗的早期关节炎患者临床和影像学结局优于3个月后治疗者。
- GC的临床和影像学疗效得到确认,口服与肠外给药疗效相似。
- 长期数据提示使用GC时需关注心血管安全性。
- 阶梯式DMARD治疗对早期关节炎长期结局与初始强化DMARD治疗同样有效。
关键数值与推荐
- 早期银屑病关节炎患者采用紧密控制相比标准治疗有更好的皮肤和关节结局。
- 强化bDMARD治疗的短期优势在停用bDMARD后未能维持。
临床怎么用
- 对早期关节炎患者可考虑运动项目以改善疼痛和躯体功能。
- 应在症状出现3个月内尽早开始药物治疗以改善临床和影像学结局。
- 甲氨蝶呤和GC可作为早期关节炎的一线药物,但长期使用GC需关注心血管安全性。
- 可采用阶梯式DMARD治疗策略,其长期结局与初始强化治疗相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To perform a systematic literature review (SLR) on pharmacological and non-pharmacological treatments, in order to inform the European League Against Rheumatism (EULAR) recommendations for the management of early arthritis (EA). METHODS: The expert committee defined research questions concerning non-pharmacological interventions, patient information and education, non-steroidal anti-inflammatory drug, glucocorticoid (GC) and disease-modifying antirheumatic drugs (DMARDs) use, as well as on disease monitoring. The SLR included articles published after the last EULAR SLR until November 2015 found in the MEDLINE, EMBASE and Cochrane databases and abstracts from the 2014 and 2015 American College of Rheumatology and EULAR conferences. RESULTS: Exercise programmes may improve pain and physical function in patients with EA. Patients with EA treated within the first 3 months of symptoms have better clinical and radiological outcomes than those treated beyond 3 months. The clinical and radiological efficacy of GCs is confirmed, with similar efficacy of oral and parenteral administrations. Long-term data raise concerns regarding cardiovascular safety when using GCs. Step-up DMARD therapy is as effective as intensive DMARD therapy 'ab initio' for the long-term outcome of EA. Short-term superiority of intensive therapy with bDMARDs is not maintained on withdrawal of bDMARD. Patients with early psoriatic arthritis have better skin and joint outcomes when tight control is used compared to standard care. CONCLUSIONS: The findings confirm the beneficial effect of exercise programmes and the importance of early drug therapy and tight control. They support the use of methotrexate and GCs as first-line drugs, although the long-term use of GCs raises safety concerns.
引用
- Daien CI, Hua C, Combe B, et al. Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis. RMD Open. 2017. PMID: 28151539. doi:10.1136/rmdopen-2016-000404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。